Plasmatic oxidative stress biomarkers in multiple sclerosis: Relation with clinical and demographic characteristics

Clinical Biochemistry

Volumn 48, Issue 1-2, 2015, Pages 19-23

  Pasquali, Livia ^a   Pecori, Chiara ^a   Lucchesi, Cinzia ^a   LoGerfo, Annalisa ^a   Iudice, Alfonso ^a   Siciliano, Gabriele ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Advanced oxidation protein products; Multiple sclerosis; Plasmatic ferric reducing ability; Relapsing remitting multiple sclerosis; Secondary progressive multiple sclerosis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DAYTIME SOMNOLENCE; DEMOGRAPHY; DISABILITY; DISEASE DURATION; DISEASE MARKER; FATIGUE; FEMALE; FERRIC REDUCING ABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; SOMNOLENCE; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXIDATIVE STRESS;

EID: 84920261474     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.09.024     Document Type: Article

References (40)

1. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
2. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8:280-291.
3. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
4. Frischer J.M., Bramow S., Dal Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
5. Witte M.E., Mahad D.J., Lassmann H., van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med 2014, 20(3):179-187.
6. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013, 333(1-2):1-4.
7. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302.
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale. Neurology 1983, 33:1444-1452.
9. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
10. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540-545.
11. Vignatelli L., Plazzi G., Barbato A., Ferini-Strambi L., Manni R., Pompei F., et al. Italian version of the Epworth Sleepiness Scale: external validity. Neurol Sci 2003, 23(6):295-300.
12. Mancuso M., Orsucci D., Logerfo A., Rocchi A., Petrozzi L., Nesti C., et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 2010, 257:774-781.
13. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
14. Hu M.L. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994, 233:380-385.
15. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76.
16. Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S., Thompson A.J., et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014, 83(3):278-286.
17. Sadowska-Bartosz I., Adamczyk-Sowa M., Galiniak S., Mucha S., Pierzchala K., Bartosz G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int 2013, 63(5):507-516.
18. Miller E., Walczak A., Saluk J., Ponczek M.B., Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 2012, 45(1-2):26-30.
19. Tasset I., Agüera E., Sánchez-López F., Feijóo M., Giraldo A.I., Cruz A.H., et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012, 45(6):440-444.
20. Ljubisavljevic S., Stojanovic I., Vojinovic S., Stojanov D., Stojanovic S., Cvetkovic T., et al. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. Neurochem Int 2013, 62(7):988-997.
21. Fiorini A., Koudriavtseva T., Bucaj E., Coccia R., Foppoli C., Giorgi A., et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS ONE 2013, 8(6):e65184.
22. Zamani A., Rezaei A., Khaeir F., Hooper D.C. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients. Clin Neurol Neurosurg 2008, 110(6):642-643.
23. Oliveira S.R., Kallaur A.P., Simão A.N., Morimoto H.K., Lopes J., Panis C., et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the Expanded Disability Status Scale. J Neurol Sci 2012, 321(1-2):49-53.
24. Besler H.T., Comoğlu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003, (3):189-196.
25. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., Capeillère-Blandin C., Nguyen A.T., Canteloup S., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161(5):2524-2532.
26. Himmelfarb J., Lazarus J.M., Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991, 17(3):271-276.
27. Loughrey C.M., Young I.S., Lightbody J.H., McMaster D., McNamee P.T., Trimble E.R. Oxidative stress in haemodialysis 1994, QJM 87(11):679-683.
28. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M., Nguyen A.T., Thévenin M., Jaudon M.C., et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996, 21(6):845-853.
29. Halliwell B., Gutteridge J.M. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 1995, 18(1):125-126.
30. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39(1):44-84.
31. Siciliano G., Piazza S., Carlesi C., Del Corona A., Franzini M., Pompella A., et al. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol 2007, 254(5):575-580.
32. Mancuso M., Bonanni E., LoGerfo A., Orsucci D., Maestri M., Chico L., et al. Oxidative stress biomarkers in patients with untreated obstructive sleep apnea syndrome. Sleep Med 2012, 13(6):632-636.
33. Induruwa I., Constantinescu C.S., Gran B. Fatigue in multiple sclerosis - a brief review. J Neurol Sci 2012, 323(1-2):9-15.
34. Sternberg Z., Hennies C., Sternberg D., Bistulfi G.L., Kazim L., Benedict R.H., et al. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler 2011, 17(2):157-163.
35. Sternberg Z., Hennies C., Sternberg D., Wang P., Kinkel P., Hojnacki D., et al. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. J Neuroinflammation 2010, 7:72.
36. Sadowska-Bartosz I., Adamczyk-Sowa M., Gajewska A., Bartosz G. Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment. J Neuroimmunol 2014, 266(1-2):67-74.
37. Koch M., Mostert J., Arutjunyan A.V., Stepanov M., Teelken A., Heersema D., et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007, 14(5):529-533.
38. Teunissen C.E., Sombekke M., van Winsen L., Killestein J., Barkhof F., Polman C.H., et al. Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler 2012, 18(8):1092-1098.
39. Yuceyar N., Taşkiran D., Sağduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 2001, 103(4):206-211.
40. Sotgiu S., Pugliatti M., Sanna A., Sotgiu A., Fois M.L., Arru G., et al. Serum uric acid and multiple sclerosis. Neurol Sci 2002, (4):183-188.